Fuad H. Al-Ghamdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fuad H. Al-Ghamdi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Ayman M Al-Qaaneh
1 shared publication- Hessah Alshammari
Department of Cardiac Sciences, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia
1 shared publication Hessah F AlShammari
Department of Anatomy and Stem Cell Unit, College of Medicine, king Saud University, Riyadh, Saudi Arabia
1 shared publication- Lama Binobaid
Department of Pharmacology and Toxicology, College of Pharmacy, Umm AlQura University, Makkah, 21955, Saudi Arabia
1 shared publication Rashed Almousa
Department of Medical Equipment Technology, College of Applied Medical Sciences, Majmaah University, Al Majmaah, 11952, Saudi Arabia
1 shared publicationSara Abou Al-Saud
Cardiac Sciences Department, College of medicine, King Saud University, Riyadh, 11451, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 49, 101483
Effect of electromagnetic waves from doxorubicin on breast cancer growth in a mouse model
- 14 October 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 49, 101483
Open AccessEffect of electromagnetic waves from doxorubicin on breast cancer growth in a mouse model
- Open Access
- 5 August 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (15) , 7783
Medication-Encoded Electromagnetic Waves as a Cardiomyogenic Cue for Human Adipose-Derived Stem Cells
This study evaluated whether medication-derived electromagnetic waves (MEMW) generated from a combination of clinically used cardiovascular drugs could produce early cardiomyogenic responses comparable to direct medication exposure in human adipose-derived stem cells (ADSCs). ADSCs were assigned to untreated control, direct-medication (salbutamol, ivabradine, valsartan, and sacubitril), or corresponding MEMW exposure groups. After 21 days, cellular morphology, crystal violet staining, and quantitative reverse-transcription PCR were assessed. Both intervention groups showed modest changes from randomly oriented fibroblast-like morphology toward more elongated and aligned arrangements. POU5F1 (OCT4), SOX2, and NANOG expression decreased, whereas the early cardiac-associated markers GATA4, NKX2-5, and NPPA increased. Changes in the late markers TNNI3 and MYH6 were smaller, indicating early cardiomyogenic commitment rather than mature cardiomyocyte differentiation. MEMW exposure therefore produced selected biological responses that broadly paralleled direct medication treatment under the conditions tested. Independent signal characterization, sham controls, protein-level validation, and functional assays are required before mechanistic or translational conclusions can be drawn.
- 5 August 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (15) , 7783
Open AccessMedication-Encoded Electromagnetic Waves as a Cardiomyogenic Cue for Human Adipose-Derived Stem Cells
This study evaluated whether medication-derived electromagnetic waves (MEMW) generated from a combination of clinically used cardiovascular drugs could produce early cardiomyogenic responses comparable to direct medication exposure in human adipose-derived stem cells (ADSCs). ADSCs were assigned to untreated control, direct-medication (salbutamol, ivabradine, valsartan, and sacubitril), or corresponding MEMW exposure groups. After 21 days, cellular morphology, crystal violet staining, and quantitative reverse-transcription PCR were assessed. Both intervention groups showed modest changes from randomly oriented fibroblast-like morphology toward more elongated and aligned arrangements. POU5F1 (OCT4), SOX2, and NANOG expression decreased, whereas the early cardiac-associated markers GATA4, NKX2-5, and NPPA increased. Changes in the late markers TNNI3 and MYH6 were smaller, indicating early cardiomyogenic commitment rather than mature cardiomyocyte differentiation. MEMW exposure therefore produced selected biological responses that broadly paralleled direct medication treatment under the conditions tested. Independent signal characterization, sham controls, protein-level validation, and functional assays are required before mechanistic or translational conclusions can be drawn.
- Open Access
- 30 June 2024
- Published by Medic Scientific in Journal of Medical pharmaceutical and allied sciences
- Vol. 13 (3) , 6603-6607
Effect of anticancer electromagnetic spectrums on the cancer cell line growths
Electromagnetic frequencies (EMF) that are generated from different electronic devices can interact with biological systems including humans. Several theories described the effects of EMF on the growth of in vitro cancer cell lines and biological systems, which revealed that EMF could inhibit cancer cell growth or decrease viability depending on the field strength and frequency. Accordingly, in this study, we are targeting to assess the effect of the anticancer-extracted electromagnetic spectrums on the growth of two types of cell lines which are the breast cancer cell line MCF-7 and human embryonic kidney HEK293 as a control cell line. Drugs digitalized electromagnetic spectrums of a mixture of anticancer medications were generated using a DigiConPro® VITATEC device emitted using the supplied antenna and applied to a 96-well culture plate containing MCF-7 and HEK293. The cell viability was performed by MTT assay after three days. The post-exposure effect of anticancers' electromagnetic spectrums was determined on the cancer cell line. Anticancers’ electromagnetic spectrums were seen to cause a statistically significant (p<0.05) decrease in the growth rate relative to the control after three days of exposure to the electromagnetic spectrums. Three doses of anticancers’ electromagnetic spectrums were applied as a dose per day, and each dose was running for 5 hours which induced a reduction in MCF-7 growth compared to the control group, while the HEK293 showed no statistically significant decrease in the growth rate. As a conclusion, electromagnetic spectrums of the anticancer medications may have the same effect as the chemical compound.
- 30 June 2024
- Published by Medic Scientific in Journal of Medical pharmaceutical and allied sciences
- Vol. 13 (3) , 6603-6607
Open AccessEffect of anticancer electromagnetic spectrums on the cancer cell line growths
Electromagnetic frequencies (EMF) that are generated from different electronic devices can interact with biological systems including humans. Several theories described the effects of EMF on the growth of in vitro cancer cell lines and biological systems, which revealed that EMF could inhibit cancer cell growth or decrease viability depending on the field strength and frequency. Accordingly, in this study, we are targeting to assess the effect of the anticancer-extracted electromagnetic spectrums on the growth of two types of cell lines which are the breast cancer cell line MCF-7 and human embryonic kidney HEK293 as a control cell line. Drugs digitalized electromagnetic spectrums of a mixture of anticancer medications were generated using a DigiConPro® VITATEC device emitted using the supplied antenna and applied to a 96-well culture plate containing MCF-7 and HEK293. The cell viability was performed by MTT assay after three days. The post-exposure effect of anticancers' electromagnetic spectrums was determined on the cancer cell line. Anticancers’ electromagnetic spectrums were seen to cause a statistically significant (p<0.05) decrease in the growth rate relative to the control after three days of exposure to the electromagnetic spectrums. Three doses of anticancers’ electromagnetic spectrums were applied as a dose per day, and each dose was running for 5 hours which induced a reduction in MCF-7 growth compared to the control group, while the HEK293 showed no statistically significant decrease in the growth rate. As a conclusion, electromagnetic spectrums of the anticancer medications may have the same effect as the chemical compound.